Novo NVO is expanding its artificial intelligence (AI) capabilities through a new collaboration with Anthropic to accelerate drug discovery and development of new medicines. Under the agreement, Novo will use Anthropic's models and Claude Science across selected research and development (R&D) workflows, while also using Anthropic's frontier models to strengthen AI-driven software development. The deal adds to Novo's growing network of technology partnerships as it seeks to integrate AI more deeply across its operations. Rationale Behind NVO's Latest Anthropic Deal The collaboration will focus on drug discovery challenges identified by Novo's scientists and computational teams.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.